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Abstract: Recent advances in the field of RNA research have provided compelling 
evidence implicating microRNA (miRNA) and long non-coding RNA molecules in many 
diverse and substantial biological processes, including transcriptional and post-transcriptional 
regulation of gene expression, genomic imprinting, and modulation of protein activity. 
Thus, studies of non-coding RNA (ncRNA) may contribute to the discovery of possible 
biomarkers in human cancers. Considering that the response to chemotherapy can differ 
amongst individuals, researchers have begun to isolate and identify the genes responsible. 
Identification of targets of this ncRNA associated with cancer can suggest that networks of 
these linked to oncogenes or tumor suppressors play pivotal roles in cancer development. 
Moreover, these ncRNA are attractive drug targets since they may be differentially 
expressed in malignant versus normal cells and regulate expression of critical proteins in 
the cell. This review focuses on ncRNAs that are differently expressed in malignant tissue, 
and discusses some of challenges derived from their use as potential biomarkers of  
tumor properties. 
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1. Introduction 
Use of predictive biomarkers should be an integral part of current clinical practice and be used as an 
aid to clinical experience and expertise in making patient therapy decisions. 
Since the first miRNA was discovered [1,2] these have been added as a new level to gene regulation 
in normal as well as pathological cell function. It is estimated that more than 30% of the human genes 
are post-transcriptionally regulated by miRNAs [3]. 
In addition to well-described microRNAs, the growing knowledge of the mammalian non-coding 
transcriptome is revealing that the genome is also replete with highly conserved large ncRNAs 
(lncRNAs), which could have a major role in the development and progression of cancer [4], although 
their mechanisms of action remain less well understood [5]. 
Given the larger and growing focus on targeting RNAs for disease therapeutics, what we do know 
about the intrinsic biology of these small RNAs (miRNA) and long non-coding RNA (lncRNA) makes 
them potentially attractive targets for pharmacologic manipulation and prognosis markers. 
The miRNA was referred initially as small temporal RNA (stRNAs) whith appearance during 
development [6]. Mature miRNAs regulate mRNA target degradation or translational repression by 
mediating sequence-specific targeting of its mRNA [7,8]. It is very important to consider that the 
number of miRNA binding sites can vary in the target mRNA affecting efficiency of translational 
repression [9]. 
In contrast to miRNAs, lncRNAs are mRNA-like transcripts ranging in length from 200 nt to  
~100 kilobases (kb) lacking significant open reading frames. Many identified lncRNAs are transcribed 
by RNA polymerase II (RNA pol II) and are polyadenylated, but this is not a fast rule [10,11]. 
Large ncRNAs were first described during large scale sequencing of full-length cDNA libraries in 
the mouse [12]. One subclass of lncRNAs is called large or long intergenic ncRNAs (lincRNAs). 
These lincRNAs are exclusively intergenic and are marked by a chromatin signature indicative of 
transcription [5,13]. They show a clear evolutionary conservation that confirms the distinctive 
biological roles developed through diverse mechanisms [14–16]. 
Less than 2% of the total genome contains only 20,000 protein-coding genes whereas a substantial 
fraction of the human genome can be transcribed, yielding many short or lncRNAs with limited 
protein-coding capacity. Between them, lincRNA are mostly identified (>3000) but a few have been 
characterized (<1%). 
Some lncRNAs are preferentially expressed in specific tissues [17]. But, compared to miRNA, 
nowadays few lincRNA has been characterized. 
To hypothesize which miRNAs could be involved in translational regulation of candidate target 
even is necessary carried out an in silico analysis of putative miRNAs. Although, let-7 represents one 
of miRNA whose targets genes as RAS [18], HMGA2 [19], MYC [20], and p16
INK4A [21] were 
specifically validated and linked to its regulatory effect. Int. J. Mol. Sci. 2012, 13 842 
 
 
Features of malignant tumors, distinct from benign tumors, include invasion and metastasis.  
miR-21 is one of the most frequently upregulated miRNAs in cancers. In colorectal cancer (CRC), 
miR-21 promotes invasion, intravasation, and metastasis by downregulating Pdcd4 [22]. 
We will focus on CRC carcinogenesis process and considering the recent up-date “the tumor 
hallmarkers” [23] describe the miRNAs and LincRNAs that have been implicated in this pathway. 
Given that a miRNAs regulate multiple targets and one target gene could be regulated by multiple 
miRNAs, a summary is difficult to make. But, in this review we intend to do a summary of the current 
knowledge by focusing on miRNA as diagnostic, predictive and prognostic biomarker in CRC. Also, a 
short section about therapeutic role of miRNA in cancer will be described. 
2. miRNAs and lincRNA Mechanism of Action 
miRNAs act throught a post-transcriptional regulation that depends on the degree of 
complementarity between a miRNA and its target. Imperfectly base-pair with sequences in the 3′-UTR 
of target mRNAs and miRNA inhibit protein synthesis by either repressing translation or promoting 
mRNA deadenylation and degradation. On the other hand, when a miRNA and an mRNA exhibits 
perfect complementarity, the target mRNA is cleaved by RISC [24]. Imperfect base pairing between a 
miRNA and its target, as occurs with most mammalian miRNAs, leads to translational silencing of the 
target [25]. However, imperfectly complementarily miRNAs can also reduce the abundance of  
mRNAs [26]. 
Prediction of miRNA targets is one of the most important fields in miRNAs research, given that 
miRNAs exert their function by regulating target mRNAs. The specificity of miRNA–mRNA 
interaction is mainly conferred by the first eight nucleotides of a miRNA (known as seed sequence). 
However, the likelihood that a predicted target is a bona fide target is influenced not only by seed 
pairing but also by other factors such as the number of target sites, the context of surrounding 
sequence in mRNA [27], and the occlusion of target sites by RNA-binding proteins [28]. Currently, 
various algorithms have been developed for predicting miRNA target interactions. [29–39]. 
Traditionally, some major characteristics such as the hairpin-shaped stem loop structure, high 
evolutionary conservation, and high minimal folding free energy are important features used in the 
computational identification of miRNAs targets. These programs indicate that each miRNA potentially 
regulates hundreds of target mRNAs [40], and it seems plausible that most, if not all, mRNAs are  
post-transcriptionally regulated by miRNAs. However, the most important problem of these 
computational algorithms remains target over-prediction. Many targets predicted by in silico analyses 
are not confirmed as real targets in biological assay. Thus, the gold standard for miRNA target 
identification is the experimental demonstration that (a) a luciferase reporter fused to the 3′-UTR of 
the predicted target is repressed by overexpression of the miRNA and (b) this repression is abrogated 
by point mutation in the target sequence(s) in the 3'-UTR [41]. 
Very little is known about lincRNA biogenesis, in contrast with miRNAs, previous mechanisms of 
processing are not necessary for lincRNAs. These long non-coding RNA are exclusively intergenic 
and are marked by a chromatin signature indicative of transcription [5,13]. Int. J. Mol. Sci. 2012, 13 843 
 
 
Mechanisms of action of lincRNAs represented by two of them closely related to cancer 
developement: lincRNA-p21 described as tumor suppressive and lincRNA-HOTAIR as oncogenic 
(Figure 1 A and B, respectively). 
Figure 1. (A) Mechanisms of gene regulation by oncogenic lincRNA HOTAIR. HOTAIR 
recruits PRC2 to specific gene promoters, inducing gene repression that leads to tumor 
metastasis; (B) Mechanisms of gene regulation by tumor-suppressor lincRNA-p21, where 
its expression is directly induced by p53. Then, lincRNA-p21 specifically interacts with 
hnRNP-K for localization to gene promoters for repression [42]. 
 
(A) 
 
(B) 
3. miRNAs, lincRNA and Cancer 
At the time of this writing it review, the latest version of the Sanger Institute miRBase (V16) [43], 
have been described 2108 human miRNA sequences [44]. 
Many evidences have indicated that miRNAs are involved in the tumorigenesis of many human 
cancers and, since their discovery, close to 3000 publications associate miRNAs to cancer, including 
over 700 reviews. 
Cancer-associated genomic regions could be disrupted by chromosomal abnormalities, which 
include minimal regions of loss of heterozygosity, regions of amplification etc. These regions affected 
genes encoding miRNAs therefore connection between altered miRNA expression and cancer has been 
proved [45].   
In this sense, the initial support for the involvement of miRNAs in cancer came from identification 
of miR-15a and miR-16a in the chromosome region 13q14, commonly deleted in human chronic 
lymphocytic leukemia (CLL). Expression analysis reported by Calin et al. [46] has indicated that  
miR-15 and miR-16 were either absent or down regulated in the 68% of CLL patients. It was later 
shown that miR-15a and miR-16-1 expression silenced the anti-apoptotic factor BCL-2, suggesting that 
their absence in CLL inhibit apoptosis by reactivation of BCL-2 [47]. For the first time, it was showed 
that miRNAs have a potential role as tumor suppressor. 
It has been predicted that miRNA regulate near 20% to 30% of genes [48]. Between these targets 
regulated by miRNA including genes involved in diverse biological processes and each of them Int. J. Mol. Sci. 2012, 13 844 
 
 
probably controls hundreds of genes. Thus, altered levels of miRNA have been shown in different 
systems, such as oncogenesis and development. Thus, a large scale of miRNA expression profiling 
analyses reveals that mature miRNAs are globally down regulated in various tumors and profiling and 
characterization studies have proved that it could be used to create signature for many malignancies 
and classify human cancer [49–54]. Therefore miRNA may inhibit or promote tumor progression 
depending on mRNA target function. On the other hand, lncRNAs are also emerging as important 
regulators in pathways that involve oncogenes and tumor suppressors. Misregulation of antisense 
ncRNAs encoded by the opposite strand of protein-coding transcript partners affect the expression of 
the sense gene [55]. Epigenetic silencing of a tumor suppresor gene by the expression of the antisense 
ncRNA could lead to pathogenesis transformation when its regulation is disrupted.   
Chromatin-regulatory complexes are linked with the aberrant proliferation of cancer cells and around 
20% of large intergenic ncRNA (lincRNAs) are associated with these chromatin-repressive complexes. 
Among them, polycomb repressive complex 2 (PRC2)’s ability to repress specific subset of target 
genes is affected when some lincRNAs are depleted [56].   
Some lincRNAs modulate tumor suppressor pathways, like linRNA-p21, directly induced by p53 to 
play a critical role in the p53 transcriptional response. LincRNA-p21 functions as a gene repressor by 
interacting with hnRNP-K protein, allowing its localization to gene promoters to be repressed by p53 [57]. 
4. miRNA Expression in CRC 
The central role of miRNAs in development and their direct effects in global gene regulation can 
indicate that miRNAs are important markers for human cancer. It has been suggested that the tumor 
miRNA profile may resemble that of their antecedent stem cells and thus reflect development lineage. 
In this sense, Lu et al. [58] analyze the expression levels of 217 miRNAs across 334 primary tumors, 
normal tissues and cell lines and their results showed that tumors display a miRNA expression profile 
reminiscent of that in the tissues from which they were derived. The miRNA profile was a better 
indicator of tissue lineage than was mRNA profile. Our understanding of miRNA function in 
mammals suggests that these molecules play a role in determination and/or maintenance of lineage 
during development. The alteration of miRNA expression in tumors samples might indicate the 
reduced differentiation that is a property in cancer. 
Colon cancer is also associated with altered miRNA expression. Michael et al. [58] identified by 
cloning technique that the expression of two mature miRNA, miR-143 and miR-145, was consistently 
reduced at the adenomatous and cancer stages of colorectal cancer. Later miRNA serial analysis of 
gene expression (miRAGE) was utilized to compare expression levels of miRNAs in two primary 
colorectal adenocarcinomas with matched normal colonic epithelia. Cummins et al. [60] identified 
over 50 differentially expressed miRNAs, and miR-145 and miR-143 were in both studies significantly 
lower in tumoral cells compared to normal colonic cells. We examined the expression of 156 mature 
miRNA, consecutively, by Real-time PCR, in a panel of 16 CRC cell lines and 12 matched-pairs of 
tumoral and non-tumoral tissues from patients [61]. We identified a subset of 13 miRNAs 
differentially expressed in CRC cell lines as well as patients matched normal and tumoral tissues; 
among them miR-145 was also identified as down-regulated in CRC tissues. Moreover, the expression 
levels of miR-31 were higher in the tumor samples and CRC cell lines in comparison to the  Int. J. Mol. Sci. 2012, 13 845 
 
 
non-tumoral samples and were related to pathological stage, suggesting that this miRNA could 
contribute to both, the tumorogenesis and the acquisition of a more aggressive phenotype in CRC. 
5. ncRNA as Regulator of Tumor Hallmarkers and Vogelstein’s Model of CRC Pathogenesis 
Many studies have highlighted the biological importance of miRNAs in CRC development, 
including genesis, progression and response to treatments. These studies have shown that many 
proteins involved in key signaling pathways of CRC, such as members of the Wnt/β-catenin and 
phosphatidylinositol-3-kinase (PI-3-K) pathways, KRAS, p53, extracellular matrix regulators, as well 
as epithelial-mesenchymal transition (EMT) transcription factors, are altered and seem to be affected 
by miRNA regulation in CRC [62]. These findings significantly extend Vogelstein’s model of CRC 
pathogenesis [63] and have shown the key role of miRNAs in CRC development. Carcinogenesis 
process, the so called “tumor hallmarkers” described by Hannahan and Weinberg [23], could be linked 
to this model in addition with miRNA role in this well know pathological process (summarized in 
Figure 2). 
Figure 2. Connection between emerging hallmarks of each acquired capabilities necessary 
for tumor growth and progression [23] and, Vogelstein’s model of CRC pathogenesis [63]. 
MicroRNAs’ involved in each way and emerging linc-HOTAIR implication in   
metastasis features. 
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The Wnt/β-catenin pathway plays a central role in an early colorectal tumor development. 
Inactivation of the adenomatous polyposis coli (APC) gene is a major initiating event in colorectal 
carcinogenesis occurring in more than 60% of colorectal adenomas and carcinomas and leading to 
stimulation of the Wnt pathway via free β-catenin [63]. As shown by Nagel et al. [64], miRNAs 
represent a novel mechanism for APC regulation in CRC. miR-135a and miR-135b decrease 
translation of the APC transcript in vitro. Of note, miR-135a and miR-135b were also found to be 
upregulated in vivo in colorectal adenomas and carcinomas and correlated with low APC levels [22]. 
These observations indicate that alteration in the mir-135 family can be one of the early events in 
CRC’s molecular pathogenesis. 
Another important key signaling pathway in CRC development is the EGFR pathway. Stimulation 
of EGFR and, subsequently, KRAS signaling lead to the activation of numerous signal transduction 
molecules initiating a cascade of downstream effectors that mediate tumor growth, survival, 
angiogenesis and metastasis in a broad spectrum of cancers, including CRC. KRAS oncogene has been 
reported to be a direct target of the let-7 miRNA family and of miR-143 [65]. More recently, miR-18a 
was observed to directly regulate KRAS but not N- and HRAS levels in the colon adenocarcinoma 
HT-29 cells [66]. Another central signaling downstream from EGFR and important in CRC 
development is the PI-3-K pathway. Studies based on microRNA arrays found a ubiquitous loss of 
miR-126 expression in CRC cell lines when compared to normal human colon epithelia and restoration 
of miR-126 expression result in a significant growth reduction [67]. The p85β regulatory subunit 
involved in stabilizing and propagating the PI-3-K signal was mechanistically proven to be a direct 
target of miR-126 [67].   
EMT is the conversion of an epithelial cell into a mesenchymal cell. Morphologically, EMT is 
characterized by a decrease of E-cadherin, loss of cell adhesion, and increased cell motility leading to 
promotion of metastatic behavior of cancer cells (including CRC) [68]. The transcriptional repressor 
zinc-finger E-box binding homeobox 1 (ZEB1) is a crucial inducer of EMT in various human tumors, 
and it recently was shown to promote invasion and metastasis of tumor cells. The functional links to 
EMT comes from members of the miR-200 family (miR-200a, miR-200b, miR-200c, miR-141 and  
miR-429). ZEB1 directly suppresses transcription of miRNA-200 family members miR-141 and  
miR-200c, which strongly activate epithelial differentiation in pancreatic, colorectal and breast cancer  
cells [66].   
Overexpressed cyclooxygenase-2 (COX-2) strongly contributes to the growth and invasiveness of 
tumor cells in patients with CRC [69]. It has been demonstrated that COX-2 overexpression depends 
upon various cellular pathways involving both transcriptional and post-transcriptional regulations. An 
inverse correlation was reported between COX-2 and miR-101 expression in CRC cell lines. It was 
demonstrated in vitro that the direct translational inhibition of COX-2 mRNA is mediated by miR-101. 
Moreover, this correlation was supported by data collected ex vivo, in which colon cancer tissues and 
liver metastases derived from CRC patients were analyzed. Impairment of miR-101 levels could 
represent one of the leading causes of COX-2 overexpression in CRC cells [69]. 
Macrophage migration inhibitory factor (MIF) is an innate cytokine, which plays a critical role  
in the host control of inflammation and immunity, and MIF could inhibit p53 tumor suppressor  
activity [68]. Interestingly, MIF has been found to play an important role in the colorectal 
carcinogenesis and hypoxia-induced apoptosis [71–73]. Recently, our group showed that MIF is a Int. J. Mol. Sci. 2012, 13 847 
 
 
potential target of miR-451 [70]. Over-expression of miR-451 in gastric cancer and CRC cells resulted 
in reduction of cell proliferation, increased their susceptibility to radiotherapy, down-regulated 
expression of MIF at both mRNA and protein level. Furthermore, an inverse connection between miR-451 
and MIF expression in biopsies of gastric tumors was observed, which suggested a role of miR-451 as 
a tumor suppressor. On the whole, miRNAs play a role in the signal pathway linking inflammation  
and tumorigenesis. 
On the other hand, we showed recently the functional effects of miR-192/215 on cell cycle, likely 
due to their pleiotropic mechanism of action, reduce the 5-fluorouracil (5-FU) activity. 5-FU is an  
S-phase specific drug and previous studies underline the determinant role of cell cycle regulation in  
5-FU sensitivity [74–76]. Moreover, we found that miR-192/215 increases p21 expression. In 
agreement with our results, CRC cell lines resistant to 5-FU had 3-fold higher p21 expression 
compared to sensitive cell lines [77].   
Our findings also suggest a potential role of these miRNAs as biomarkers in CRC. According with 
recent studies [78,79], we found an anti-proliferative effect of miR-192/215 overexpression in CRC 
cell lines. Braun et al. [79] found that the expression of miRNA-192/215 was down-regulated in 
cancer tissue compared to normal mucosa. Moreover, two studies found a downregulation of miR-192 
in CRC tissues when compared to the normal colon [80,81]. This evidence highlights the important 
role of miR-192 in CRC development and supports the idea that miR-192 might carry out a tumor 
suppression function. Moreover, cell cycle arrest in response to DNA damage is an important  
anti-tumorigenic mechanism. Several miRNAs were shown to play key regulatory roles in cell cycle 
progression. For example, miR-34a is induced in response to p53 activation and mediates G1 arrest by 
down-regulating multiple cell cycle–related transcripts. Braun et al. [79], using a direct pharmacologic 
activator of p53 identified two clusters of miRNAs comprising miR-192/215 regulated by p53. The 
same miRNAs were also up-regulated by DNA damage in a p53-dependent fashion like miR-34a [78], 
and in accordance with our results, activation of miR-192/215 induces cell cycle arrest, suggesting that 
these miRNAs operate in the p53 network. Furthermore, Georges et al. [78] define a downstream gene 
expression signature for miR-192/215 expression, which includes a number of transcripts that regulate 
G1 and G2 checkpoints. Of these transcripts, 18 transcripts are direct targets of miR-192/215; finally, 
the authors concluded that observed cell cycle arrest most likely results from a cooperative effect 
among the modulations of these genes by the miRNAs. 
Regarding lincRNAs, a recent study reports association of HOTAIR expression and poor prognosis 
in CRC [82]. They measured Hotair expression by quantitative real time PCR in 100 colon cancer 
tissue samples matched normal tissue and report significant difference between them. When they 
considered only tumor samples and divide then between lower and higher Hotair expression, strong 
association was found between high expression and liver metastasis and poor patient prognosis. 
Moreover, cDNA microarrays from a specific subgroup of CRC samples obtained by laser micro 
dissection (LMD) suggested that Hotair expression induced genome-wide re-targeting of PRC2 in this 
CRC study group. Finally, in vitro studies confirmed invasion promotion by Hotair over-expression. 
Thus, the increase of undifferentiated cancer cells could be stimulated by Hotair expression changing 
the regulation of multiple genes by the loss of cooperation with PRC2 complex.   
Altogether these studies underscore the key role of miRNAs and recent described lincRNA in 
cancer development, including CRC. To improve the knowledge of the roles of miRNAs in CRC Int. J. Mol. Sci. 2012, 13 848 
 
 
pathogenetic pathways, functional effects of particular miRNAs have been successfully studied 
showing that epigenetic regulation by miRNAs and some lincRNA (as HOTAIR) in CRC is highly 
critical and complex (Figure 2). 
6. miRNA and Chemoresistance 
Comparison of the expression patterns of miRNAs and the potency patterns of 3089 chemical 
compounds has shown significant correlations, suggesting that miRNAs have a role in 
chemoresistance [83]. First, miRNAs expression was measured in 60 human cancer cell lines (the 
NCI-60) previously used to screen >100,000 compounds as potential anticancer drug agents. 
Correlations between microRNA expression and compound potencies suggested potentially relevant 
drug-microRNA pairs. Finally, three microRNAs known as oncomiRs, mir-21, let-7i, and mir-16, were 
transfected in three of NCI-60 cell lines and the effect of their expression on the potencies of a number 
of compounds with anticancer activity was tested showing a substantial role for microRNAs in 
anticancer drug response and suggesting a novel potential approach to the improvement of 
chemotherapy [84]. 
Resistance of cancer cells to chemotherapy continues to be a major clinical obstacle to the 
successful treatment of cancer [85]. At present, the anticancer drug resistance is considered as a 
multifactorial phenomenon involving several major mechanisms [86]. Causes of cancer specific drug 
resistance are currently believed to be linked to the random drug-induced mutational events (genetic 
hypothesis), to the drug-induced non-mutational alterations of gene function (epigenetic hypothesis), 
and, recently, to the drug-induced karyotypic changes [87–91]. Different pathway have been described 
as implicated in drug cancer resistance such as decreased uptake of water-soluble drugs, increased 
repair of DNA damage, reduced apoptosis, altered metabolism of drugs and increased energy-dependent 
efflux of chemotherapeutic drugs that diminish the ability of cytotoxic agents to kill cancer cell, 
changes in glutathione transferase, topoisomerase II and in microtubule related genes expression. 
Cancer stem cells (CSC) are a small subpopulation of cells identified in a variety of tumors that are 
capable of self-renewal and differentiation. Deregulation of stem cell self-renewal is a likely 
requirement for the initiation and formation of cancer. Furthermore, cancer stem cells are proving to be 
a very likely cause of resistance to current cancer treatments, as well as relapse in cancer patients. 
Genetic, epigenetic and the post-transcriptional regulation by miRNAs of genes involved in CSC 
maintenance, also contribute to drug resistance.   
Ragusa et al. [92] found that miR-146b-3p and miR-486-5p were more abundant in mutant KRAS 
patients compared with wild-types suggesting that these miRNAs are involved in EGFR pathway. 
They also investigated miRNAs profiling in two human CRC cell lines, one sensitive and the other 
resistant to cetuximab (Caco-2 and HCT-116, respectively). Caco-2 and HCT-116 miRNAs profile 
was also studied after treatment with cetuximab. The authors suggested that the down-regulation of  
let-7b and let-7e and up-regulation of miR-17-3p were potential predictive markers of cetuximab 
resistance. However, until now, no clinical data confirms these findings.   
Let-7g and miR-181b were also shown to be associated with chemosensitivity to S-1 (a pro-drug of 
5-FU) based chemotherapy in colon cancer. The roles of let-7g and miR-181b in chemosensitivity are 
associated with their regulation of several genes such as RAS, cyclin D, C-MYC, E2F and  Int. J. Mol. Sci. 2012, 13 849 
 
 
cytochrome C [93]. These genes have been shown to be important for the transduction of cell signals, 
the control of cell cycle and chemosensitivity. However, the detailed molecular and cellular 
mechanisms of let-7g and miR-181b in mediating translational control will require further studies to 
elucidate the link of these miRNAs in chemosensitivity to fluoropyrimidine-based drugs in   
colon cancer. 
MiR-34a was identified as one of the down-regulated miRNAs in human CRC 5-FU-resistant DLD-1 
cells compared with those in the parental DLD-1 cells. miR-34a was also found down-regulated in 
drug resistant prostate cancer cells and ectopic miR-34a expression resulted in cell cycle arrest and 
growth inhibition and attenuated chemoresistance to the anticancer drug camptothecin [94]. 
Recently, Valeri et al. [95] demonstrated that miR-21 targets and down-regulates the core MMR 
recognition protein complex, human mutS homolog 2 (hMSH2) and 6 (hMSH6). Colorectal tumors 
that express a high level of miR-21 display reduced hMSH2 protein expression. MMR impairment 
appears to cause reduced incorporation of 5-FU metabolites into DNA, leading to reduced G2/M arrest 
and apoptosis after 5-FU treatment. Cells that overexpress miR-21 exhibit significantly reduced  
5-FU-induced G2/M damage arrest and apoptosis that is characteristic of defects in the core MMR 
component. These results were confirmed in xenograft studies demonstrating that miR-21 
overexpression dramatically reduces the therapeutic efficacy of 5-FU. These studies suggest that the 
downregulation of the MMR mutator gene associated with miR-21 overexpression may be another 
important clinical indicator of therapeutic efficacy of 5-FU in CRC. 
Another study determined that 5-FU and oxaliplatin (L-OHP) down-regulated the expression of 
miR-197, miR-191, miR-92a, miR-93, miR-222 and miR-826 in HCT-8 and HCT-116 colon cancer 
cells [96]. These results indicate that 5-FU and L-OHP mechanism of action could rely in part on their 
influence on the down-regulated miRNA expression providing novel molecular markers. 
Svoboda et al. [97] reported that median levels of miR-125b and miR-137 were upregulated in 
rectal cancer patients after a short-course of capecitabine-based chemoradiotherapy, and higher 
induction of miR-125b and miR-137 were associated with worse response to the treatment. For the 
first time, in this clinical study the miRNAs modification during therapy in patients with rectal cancer 
undergoing chemoradiotherapy with capecitabine was investigated. Importantly, while a number of 
these miRNAs showed distinct variation two weeks after starting therapy, showing profound  
inter-tumoral variability, miR-125b and miR-137 demonstrated a significant induction and similar 
expression trends. The increased levels of both miRNAs correlated with minor response to therapy and 
with higher, post-surgery, tumor stage suggesting that higher induced levels of miR-125b and  
miR-137 might be associated with worse response to radiotherapy with capecitabine. 
Many efforts have been exerted in analyzing the role of miRNAs in the development of drug 
resistance in a variety of malignancies, including CRC. Several research groups have shown that the 
expressions of miRNAs in chemoresistant cancer cells and their parental chemosensitive ones are 
different. The molecular targets and mechanisms of chemosensitivity and chemoresistance are also 
successfully studies. These results suggest a great potential for miRNAs as predictive biomarkers and 
chemotherapy modulators. Int. J. Mol. Sci. 2012, 13 850 
 
 
7. SNPs and miRNA 
Although single-nucleotide polymorphisms (SNPs) in miRNA regions are rare and considered 
unlikely to be functionally important [98] nucleotide variations within the seed sequence of the 
miRNA or on primary (pri) and precursor (pre) miRNAs might affect its processing and ultimately 
lead to modification of its expression [99]. Therefore, it is plausible that SNPs in miRNA biogenesis 
machinery genes and miRNA-containing genomic regions may affect thousands of target mRNAs, 
these or their targets might represent ideal candidate biomarkers implicated in cancer development, 
prognosis and prediction of cancer patients clinical outcome.   
In this sense, SNPs in miRNA-biogenesis genes might affect the expression of mature miRNAs and 
consequently miRNA-mediated regulation within the cell. 
Recently, we developed a study of SNPs involved in miRNA biogenesis in a group of CRC patients 
homogenously treated with 5-Fluorouracil plus Irinotecan to investigate whether these polymorphisms may 
influence the outcome of metastatic colorectal cancer (mCRC) patients [100]. We found that the SNP 
rs7372209 in miR-26-a-1 was associated with overall response rate and time to progression (ORR and 
TTP, respectively). Allele C appears to be a favorable factor, as was confirmed comparing the median 
TTP of CC+CT genotypes to the homozygote variant (TT). Furthermore, the SNP rs1834306 in the  
5′-UTR region of pri-miR-100 and the SNP rs11077 in the XPO5 gene (Xportin 5) were also found to 
be associated with TTP and DCR (disease control rate), respectively. 
Interestingly, when we performed the in silico analysis for putative target genes of these miRNAs, 
we found that some of them have been implicated in colon tumorigenesis and clinical outcome. 
On the other hand, the first epidemiological study showing an association between   
microRNA-binding SNP sequences and cancer risk was performed by Landi and co-workers [101] 
through a case-control study that examined the association of eight polymorphisms within   
microRNA-binding sites with the risk of sporadic CRC, founding that the variant alleles of CD86 and 
INSR genes were strongly associated with the risk of CRC. 
In a more recent study of early stage CRC patients, a SNP in a let-7 miRNA complementary site 
(LCS6) in the KRAS 3’untranslated region (KRAS-LCS6) genotype combined with KRAS mutations 
seemed to affect survival in metastatic patients [102]. Although this result could be considered 
interesting concerning patients’ outcome, it also merits to be validated as a prognostic biomarker and 
to be considered in therapy-decision-making. 
8. miRNAs as Predictive and Prognostic Biomarkers in CRC 
A number of studies based on expression profiling have proven that there are significant changes of 
miRNA expression levels in CRC tissue in comparison to normal colorectal epithelium. Moreover, 
comparing miRNAs expression in groups of patients with different clinical outcome have been 
identified several miRNAs with prognostic value.   
Recent studies on miRNAs have shown that the expression levels of different miRNAs, such as 
miR-21, miR-320, miR-498, miR-106a and miR-200c correlate with the probability of recurrence-free 
survival in CRC stage II-III. Schetter et al. [80] compared miRNA expression patterns in stage II 
colonic adenocarcinoma and adjacent normal tissue using a test set and two validation cohorts. In one Int. J. Mol. Sci. 2012, 13 851 
 
 
of the cohorts, a high tumor to normal expression ratio of miR-20a, miR-21, miR-106a, miR-181b and 
miR-203 was associated with poor survival. In the second validation set, including stage III, survival 
analysis showed that higher miR-21 expression predicted poorer survival in treated colonic cancer and 
poor responsiveness to adjuvant chemotherapy.   
Similar associations have been found by other research group. Schepeler and colleagues [103] 
showed that miR-320 or miR-498 expression was significantly associated with progression-free 
survival in stage II CRC. These miRNAs were found to be independent predictors of recurrence-free 
survival when stratified for age, sex, tumor stage, differentiation and histological grade.   
Another study found that miR-21 and miR-31 were significantly up-regulated, and miR-143 and 
miR-145 down-regulated in tumors compared with the normal counterparts. High expression of  
miR-21 was associated with lymph node positivity and distant metastases and tumors >50 mm in 
maximal tumor diameter were related to lower expression of miR-143 and miR-145 [104,105]. The 
expression level of miR-31 was correlated with the stage of CRC [59]. Further study confirmed this 
result showing that miR-31 expression was positively related to advanced TNM stage and deeper 
invasion of tumors, suggesting over-expression of miR-31 might be involved in the development and 
progression of CRC [104]. In addition, miR-18a was found to imply a poorer clinical prognosis [106].   
Some groups also demonstrated that miRNAs expression is associated with microsatellite status in 
CRC. Twenty-three colon cancer samples characterized by microsatellite stability (MSS), and 16 by 
high MSI were studied for genome-wide expression of miRNA and mRNA. Eight miRNAs was found 
correctly distinguish MSI-H versus  MSS colon cancer samples based on combined miRNA and 
mRNA gene expression [107]. 
In Table 1 we summarized some of the most important miRNAs found associated to CRC  
clinic-pathological features and clinic outcome.   
Table 1. Relevant miRNAs found deregulated in CRC expression profiling. 
miRNA  Dysregulation  Clinical-related phenotypes  Reference 
Let-7g  Upregulated in CRC  Higher level associated with poor S-1 response  [93] 
miR-18a  Upregulated in CRC  Higher level associated with poor overall survival  [106] 
miR-21 
Upregulated in adenoma, CRC, 
and liver metastasis tissue 
Higher level associated with lymph node positivity, 
metastasis; poor survival, poor therapeutic outcomes, 
rapid recurrence; shorter disease-free interval 
[80,105] 
miR-31  Upregulated in CRC 
Higher level associated with higher TNM stages and 
local invasion   
[61,105,108] 
miR-106a  Upregulated in colon cancer 
Higher level associated with longer disease-free 
survival and overall survival 
[80] 
miR-143 
Downregulated in colon cancer 
and liver metastasis tissue 
Lower level associated with larger tumor size and 
longer disease-free interval 
[105,106,108]
miR-145  Downregulated in CRC 
Lower level associated with larger tumor size; related 
with tumor location 
[105,106,108]
miR-181b  Upregulated in CRC  Higher level associated with poor S-1 response  [93] 
miR-320  Downregulated in MSS tumor 
Lower level associated with shorter progression-free 
survival 
[103] 
miR-498  Downregulated in MSS tumor 
Lower level associated with shorter progression-free 
survival 
[103] Int. J. Mol. Sci. 2012, 13 852 
 
 
Overall, these findings suggest that a growing number of miRNAs appear on the potential 
biomarker candidates list for CRC. An important advantage of using miRNAs for biomarker 
identification is the stability of the miRNAs in archival specimens. This is a key factor in large-scale 
retrospective biomarker discovery studies. The different length of formalin fixation time and paraffin 
embedding has little impact on miRNA stability. This is evidently explained both by the shortness of 
the molecules as well as protection from degradation by intimate RNA-protein interactions. Other 
factors may be that miRNA sequences could have evolved to elude RNA nucleases. Whereas mRNA 
tends to be labile in fixed and/or embedded tissue [109], a number of studies have shown robust 
correlations between miRNA profiling results in fresh, versus in formalin fixed paraffin-embedded 
(FFPE) tissue [110,111]. This ensures that miRNA biomarker discovery using archival FFPE 
specimens with a large sample size is feasible. miRNAs were also found to be stable in blood and body 
fluids, which has expanded the biomarker discovery sample types [112]. Moreover, recent findings 
have proven that, due to miRNAs stability, stool miRNA detection might be used as a new diagnostic 
biomarker for early CRC detection [113].   
Under disease conditions such as cancer, miRNAs entered circulation predominantly from tumor 
cells [114]. Recent studies indicated that tumor-derived miRNAs are resistant to endogenous 
ribonuclease activity detectable in plasma/serum. Thus, body fluids were also found to be a stable 
sample source for this study. 
Studies developed three years ago showed potential use of miRNAs as novel candidates of 
diagnostic and/or prognostic “circulating marker” of several cancer types [108,112,114–116]. Its 
remarkable stable form and the possibility of extraction from serum samples make them reproducible 
and consistent among individuals [117].   
Although the analysis of circulating miRNAs from serum over plasma or even whole blood are 
promising for systemic miRNA study, their future application for diagnosing or prognosis of human 
cancers is questionable and there is no consensus on the optimal circulating medium or isolation 
technique from which to quantify these miRNAs. Accumulating evidence supports miR-16  as a 
potentially ideal normalizing miRNA gene. This is abundantly expressed in blood and many solid 
tissues have been shown to reveal expression in tumor and normal specimens by several   
authors [115,117]. Despite miRNAs frequently being chosen for blood-based qRT-PCR analysis, this 
is a contentious yet critical issue and the ideal normalization control for this has not yet received a 
consensus [118]. 
9. miRNAs as “One Plus” Potential Cancer Therapeutic Targets 
The fact that miRNA dysregulation in cancer has a pathogenic effect provides the rationale for 
using miRNAs as potential therapeutic targets in cancer. 
Typically, miRNAs that serve as oncogenes are present at high levels in tumors, which inhibit the 
transcription of genes encoding tumor suppressors. Conversely, tumor suppressor miRNAs are present 
at low levels, resulting in the overexpression of transcripts encoded by oncogenes.   
For miRNAs with oncogenic capabilities, potential therapies include anti-miRNA oligonucleotides, 
microRNA sponges, miRNA masking, and as small molecule inhibitors. For tumor suppressor 
miRNAs, restoring suppressor miRNAs by forced expression of those miRNAs may be a useful Int. J. Mol. Sci. 2012, 13 853 
 
 
strategy. In several tumor types with global decreasing miRNA biogenesis, approaches to enhance 
miRNA biogenesis processing can also represent a valid therapeutic action.   
The binding of miRNAs to their mRNA binding targets are simply and elegantly governed by the 
rules of Watson–Crick base pairing. Therefore, an obvious inhibitory molecule of miRNA is  
anti-miRNA oligonucleotides (AMOs) which blocks the interactions between miRNA and its target 
mRNAs by competition. AMOs are chemically modified in a variety of ways, such as with locked 
nucleic acid (LNA) [119], 2'-O-methyl- [120], and 2'-O-methoxyethyl-modified (2'-MOE) 
oligonucleotides [121], to improve their stability and to reduce their degradation.  
A critical role of mir-21 in cell proliferation by down-regulating the tumor suppressor genes Tpm1 
and PTEN has been suggested in [122]. In this way, mir-21 represents one of the first examples of 
inhibiting cancer development by down-regulating its oncogenic miRNA activity. Using a xenograft 
carcinoma model, Si et al. [123] injected MCF-7 cells transiently transfected with 2-O-methyl 
oligonucleotides complementary to mir-21 and found that tumors derived from MCF-7 cells 
transfected with anti-mir-21 were 50% smaller in size than control MCF-7 tumor.   
Small molecule inhibitors against specific miRNAs have also been investigated. Gumireddy et al. 
identified azobenzene as a specific and efficient inhibitor of biogenesis of mir-21 from a screening. 
Such specific inhibitors of the miRNA pathway provide, not only unique tools for the investigation of 
miRNA function, but also promising reagents to boost patient response to existing chemotherapies or 
stand-alone cancer drugs [124]. However, the in vivo efficacy of such small-molecule inhibitors needs 
to be explored. 
Other inhibitory molecules correspond to microRNA sponge, a synthetic mRNA containing 
multiple binding sites for an endogenous miRNA, therefore preventing the interaction between 
miRNA and its endogenous targets. Thus, to increase the efficacy of AMOs, Ebert et al. [125] 
engineered such molecules by inserting a bulge between the microRNA binding sites at the position 
normally cleaved by Argonaute 2, enabling stable association of microRNA sponges with 
microribonucleoprotein complexes loaded with the corresponding micro-RNA. In in vitro experiments, 
these “sponges” strongly derepressed miRNA targets, but their efficacy in vivo still needs to 
be evaluated. 
Consider that each miRNA may regulate hundreds of genes, and each gene can be regulated by 
multiple miRNAs, the possibility that miRNAs can affect multiple targets with a single hit, represents 
an advantage of miRNAs over siRNA/shRNAs (small interfering RNA and short hairpin RNA, 
respectively). However, similar to siRNA/shRNAs, miRNAs may also interact with multiple targets 
and this effect is seen as a disadvantage, because off-target effects are largely unpredictable. Similar to 
endogenous miRNA, the action of AMOs is sequence-specific but not gene-specific. Thus, AMOs may 
elicit off-target side effects and unwanted toxicity. Xiao et al. [126] designed alternative strategy 
called “miR-Mask” which refers to a sequence with perfect complementarity to the binding site for an 
endogenous miRNA in the target gene, which can form a duplex with the target mRNA with higher 
affinity, therefore blocking the access of endogenous miRNA to its binding site without the potential 
side effects of mRNA degradation by AMOs.   
On the other hand, restoring expression of miRNAs with tumor suppressive properties might be a 
successful strategy and can be achieved by transfecting miRNA mimics either directly or through 
vectors. For example, to re-introduce miR-34 and its tumor suppressor capabilities, transfection with Int. J. Mol. Sci. 2012, 13 854 
 
 
miR-34 mimics into cancer cells was shown to block the cell cycle in the G1 phase, significantly 
increasing activation of caspase-3, and knocked down its downfield targets of bcl-2, Notch, and  
HMGA2 [127]. The miRNA mimic, is therefore restored miR-34 with its tumor suppressor potential; 
however, the transfection of the miR-34 mimics can only last a couple of days and the long-term 
biological effects were not observed very effectively. To overcome this dilemma, the cancer cells were 
infected with a lentivirus that expressed miR-34a. This generated stable cells expressing miR-34a. The 
lentiviral miR-34a was found to be able to inhibit cancer cell growth and tumorsphere formation [127]. 
Given the role of miRNAs deregulation in cancer stem cells, restoring the expression of miRNAs 
specifically down-regulated in CSC has been developed. In this sense, a lentiviral system restored the 
tumor suppressor effect of miR-34 in pancreatic cancer stem cells [128]. Therefore, miRNA mimics 
and lentiviral miRNAs show great potential in restoring tumor suppressor miRNAs to correct the 
dysregulation of critical genes in cancer, including cancer stem cells. 
However, from a clinical/translational research point of view, for the miRNA-based therapeutics to 
be effective, the efficient and functional delivery of miRNA mimics and/or antagonists to tumor 
remains a great challenge. In this sense, viral and non-viral delivery systems have been developed.   
Viral vector-directed methods show high gene transfer efficiency but are deficient in several areas. 
The limitations of a viral approach are related to their lack of tumor targeting and to residual viral 
elements that can be immunogenic, cytopathic, or recombinogenic. On the other hand, non-viral gene 
transfer vectors could circumvent some of the problems associated with viral vectors. Progress has 
been made toward developing non-viral, pharmaceutical formulations of gene therapeutics for in vivo 
human therapy, particularly cationic liposome mediated gene transfer systems. One disadvantage of 
cationic liposomes is that they lack tumor specificity and have relatively low transfection efficiencies 
as compared to viral vectors. However, this can be dramatically increased when the lipoplexes bear a 
ligand recognized by a cell surface receptor [129,130]. Receptor mediated endocytosis represents a 
highly efficient internalization pathway in eukaryotic cells. Non-Viral Delivery: More recently, a 
method of miRNA delivery using polyethylenimine (PEI)-mediated delivery of unmodified miRNAs was 
reported. After systemic or local application of low molecular weight PEI/miRNA complexes, intact 
miR-145 and miR-33 molecules were delivered into mouse xenograft tumors where they caused 
profound anti-tumor effects. miR-145 delivery reduced tumor proliferation and increased apoptosis, 
with concomitant repression of c-Myc and ERK5 as novel regulatory target of miR-145. Similarly, 
systemic injection of PEI-complexed miR-33a was validated as a novel therapeutic targeting method 
for Pim-1, with anti-tumor effects comparable to PEI/siRNA-mediated direct in vivo knockdown of 
Pim-1 in the model. These findings demonstrate that chemically unmodified miRNAs complexed with 
PEI can be used in an efficient and biocompatible strategy of miRNA replacement therapy, as 
illustrated by efficacious delivery of PEI/miR-145 and PEI/miR-33a complexes in colon   
carcinoma [131]. 
Therapeutic delivery of synthetic mi-RNA, using a neutral lipid emulsion (NLE), exhibited  
tumor-inhibitory effects of let-7  and miR-34 formulations in an autochthonous transgenic mouse 
model of lung cancer. This model is based on oncogenic KRAS
G12D that is expressed from a Cre 
recombinase dependent allele (LSL-KRAS G12D) containing native 5′ and 3′ untranslated regions. The 
results show that systemic delivery of miR-34a mimics can effectively cause reduction of advanced 
lung tumors in a Kras activated NSCLC mouse model through inhibition of proliferation and induction Int. J. Mol. Sci. 2012, 13 855 
 
 
of apoptosis. Where, let-7 treated tumors showed reduced proliferation. Consider that these miRNA 
might affect distinct cancer pathways and frequent downregulation in human lung tumors, then the 
combination of both let-7 and miR-34a might yield superior therapeutic effects [132]. Besides, NLE 
delivery systems are less toxic than those containing cationic lipids and have more advantages, such as: 
non-accumulation of miRNA in the liver, being less likely to form aggregates in biofluids or be taken 
up by scavenging macrophages [133]. 
Through pre-clinical assays, it was established that small-interfering RNA (siRNA) molecules 
could be delivered to prostate tumor cells in a bone metastatic site using an atelocollagen delivery 
method. Further, reduced expression of cancer-related genes in miR-16-transfected prostate cancer 
cells was analyzed and verified that genes associated with cell-cycle progression were mostly down 
regulated by synthetic miR-16. In this study, atelocollagen facilitates the accumulation of enough 
synthetic miRNA in the cancer cells. These results suggest the therapeutic potency of miR-16 in bone 
metastatic prostate cancer [134]; although some discrepancies between other miRNA and vector types’ 
influence can be implicated in growth inhibition [135]. 
Another more recent pre-clinical study, identified and validated miR-34a as a novel therapeutic 
agent against prostate cancer stem cells (CSCs) by direct functional targeting of CD44 cells [136]. 
Where, overexpression of miR-34a exerts a negative effect over CD44
+ prostate cancer cells acting as 
potent antitumor and antimetastasis in this cancer type. The most up-to-date molecular diagnostic 
cancer research findings [137], point to miR-34a expression and p53 status in lung cancer patients as 
the most promising prognostic marker. 
Finally, with all the efforts and advances made in developing miRNA-mediated therapy, two major 
hurdles still remain. The first is to maintain target specificity. It is especially challenging since  
off-target gene silencing only requires partial complementary binding between miRNA and   
protein-coding transcripts. Therefore, it is important to evaluate the effect of a specific miRNA-
mediated therapy on a proteome-wide scale to prevent unwanted gene alteration.   
The second hurdle is to achieve high therapeutic efficiency. Two factors that can limit miRNA 
therapeutic efficiency is the amplitude of target gene modulation and the number of cells that can be 
targeted. To address the first limitation, one should optimize target gene selection as well as 
therapeutic molecule design. The second limitation comes from delivery efficiency.   
Altogether these studies have indicated that miRNAs can serve as novel therapeutic targets for 
cancer. However, many challenges remain open. Although this kind of therapy is still a long way  
from fruition, as many issues need to be addressed before it can be successfully pursued, there is  
no doubt that we are at the dawn of a better understanding of key regulatory mechanisms in human 
gene regulation. 
10. Summary 
Differential expression of miRNA in cancer could be useful in the diagnosis and may distinguish 
between malignant and reactive lesions [138]. Moreover, given that the complex mechanism of gene 
regulation by microRNAs is profoundly influenced by variations in gene sequences (polymorphisms) 
of the target sites, it may indicate that miRNA expression could be influenced not only by tumor types, 
but also by individual variability related to ethnic geographical region.   Int. J. Mol. Sci. 2012, 13 856 
 
 
On the other hand, in considering critical roles for chromatin-modifying complexes in the 
establishment and maintenance of cells pluripotency, the possibility of lincRNAs interactions with 
these complexes could impart target specificity. LincRNAs (as HOTAIR) could represent an additional 
layer of complexity in the networks controlling cellular differentiation. 
Lastly, miRNA-based cancer therapy is a very interesting field of investigation that offers the 
appeal of targeting multiple gene networks controlled by a single miRNA such as described by Henry 
JC reviews [139]. 
References 
1.  Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small 
RNAs with antisense complementarity to lin-14. Cell 1993, 75, 843–854. 
2.  Wightman, B.; Ha, I.; Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 
by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993, 75, 855–862. 
3.  Filipowicz, W.; Bhattacharyya, S.N.; Sonenberg, N. Mechanisms of post-transcriptional 
regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 2008, 9, 102–114. 
4.  Perez, D.S.; Hoage, T.R.; Pritchett, J.R.; Ducharme-Smith, A.L.; Halling, M.L.; Ganapathiraju, S.C.; 
Streng, P.S.; Smith, D.I. Long, abundantly expressed noncoding transcripts are altered in cancer. 
Hum. Mol. Genet. 2008, 17, 642–655. 
5.  Guttman, M.; Amit, I.; Garber, M.; French, C.; Lin, M.F.; Feldser, D.; Huarte, M.; Zuk, O.; 
Carey, B.W.; Cassady, J.P.; et al. Chromatin signature reveals over a thousand highly conserved 
large non-coding RNAs in mammals. Nature 2009, 458, 223–227. 
6.  Lagos-Quintana, M.; Rauhut, R.; Lendeckel, W.; Tuschl, T. Identification of novel genes coding 
for small expressed RNAs. Science 2001,294, 853–858. 
7.  Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small 
RNAs with antisense complementarity to lin-14. Cell 1993, 75, 843–854. 
8.  Bartel, D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281–297. 
9.  John, B.; Enright, A.J.; Aravin, A.; Tuschl, T.; Sander, C.; Marks, D.S. Human MicroRNA 
targets. PLoS Biol. 2004, 2, e363. 
10.  Cheng, J.; Kapranov, P.; Drenkow, J.; Dike, S.; Brubaker, S.; Patel, S.; Long, J.; Stern, D.; 
Tammana, H.; Helt, G.; et al. Transcriptional maps of 10 human chromosomes at 5-nucleotide 
resolution. Science 2005, 308, 1149–1154. 
11.  Wu, Q.; Kim, Y.C.; Lu, J.; Xuan, Z.; Chen, J.; Zheng, Y.; Zhou, T.; Zhang, M.Q.; Wu, C.I.; 
Wang, S.M. Poly A- transcripts expressed in HeLa cells. PLoS One 2008, 3, e2803. 
12.  Okazaki, Y.; Furuno, M.; Kasukawa, T.; Adachi, J.; Bono, H.; Kondo, S.; Nikaido, I.; Osato, N.; 
Saito, R.; Suzuki, H.; et al. Analysis of the mouse transcriptome based on functional annotation 
of 60,770 full-length cDNAs. Nature 2002, 420, 563–573. 
13.  Khalil, A.M.; Guttman, M.; Huarte, M.; Garber, M.; Raj, A.; Rivea Morales, D.; Thomas, K.; 
Presser, A.; Bernstein, B.E.; van Oudenaarden, A.; et al. Many human large intergenic 
noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. 
Proc. Natl. Acad. Sci. USA 2009, 106, 11667–11672. Int. J. Mol. Sci. 2012, 13 857 
 
 
14.  Brannan, C.I.; Dees, E.C.; Ingram, R.S.; Tilghman, S.M. The product of the H19 gene may 
function as RNA. Mol. Cell. Biol. 1990, 10, 28–36. 
15.  Rinn, J.L.; Kertesz, M.; Wang, J.K.; Squazzo, S.L.; Xu, X.; Brugmann, S.A.; Goodnough, L.H.; 
Helms, J.A.; Farnham, P.J.; Segal, E.; et al. Functional demarcation of active and silent 
chromatin domains in human HOX loci by noncoding RNAs. Cell 2007, 129, 1311–1323. 
16.  Willingham, A.T.; Orth, A.P.; Batalov, S.; Peters, E.C.; Wen, B.G.; Aza-Blanc, P.; Hogenesch, J.B.; 
Schultz, P.G. A strategy for probing the function of noncoding RNAs finds a repressor of NFAT. 
Science 2005, 309, 1570–1573. 
17.  Mercer, T.R.; Dinger, M.E.; Sunkin, S.M.; Mehler, M.F.; Mattick, J.S. Specific expression of 
long noncoding RNAs in the mouse brain. Proc. Natl. Acad. Sci. USA 2008, 105, 716–721. 
18.  Johnson, S.M.; Grosshans, H.; Shingara, J.; Byrom, M.; Jarvis, R.; Cheng, A.; Labourier, E.; 
Reinert, K.L.; Brown, D.; Slack, F.J. RAS is regulated by the let-7 microRNA family. Cell 2005, 
120, 635–647. 
19.  Lee, Y.S.; Dutta, A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. 
Genes Dev. 2007, 21, 1025–1030. 
20.  Sampson, V.B.; Rong, N.H.; Han, J.; Yang, Q.; Aris, V.; Soteropoulos, P.; Petrelli, N.J.;  
Dunn, S.P.; Krueger, L.J. MicroRNA let-7a down-regulates MYC and reverts MYC-induced 
growth in Burkitt lymphoma cells. Cancer Res. 2007, 67, 9762–9770. 
21.  Lan, F.F.; Wang, H.; Chen, Y.C.; Chan, C.Y.; Ng, S.S.; Li, K.; Xie, D.; He, M.L.; Lin, M.C.; 
Kung, H.F. Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation 
of c-Myc and upregulation of p16 (INK4A). Int. J. Cancer 2011, 128, 319–331. 
22.  Corney, D.C.; Flesken-Nikitin, A.; Godwin, A.K.; Wang, W.; Nikitin, A.Y. MicroRNA-34b and 
MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and   
adhesion-independent growth. Cancer Res. 2007, 67, 8433–8438. 
23.  Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 2011, 144, 646–674. 
24.  Gregory, R.I.; Chendrimada, T.P.; Cooch, N.; Shiekhattar, R. Human RISC couples microRNA 
biogenesis and posttranscriptional gene silencing. Cell 2005, 123, 631–640. 
25.  Hutvagner, G. Small RNA asymmetry in RNAi: function in RISC assembly and gene regulation. 
FEBS Lett. 2005, 579, 5850–5857. 
26.  Lim, L.P.; Lau, N.C.; Garrett-Engele, P.; Grimson, A.; Schelter, J.M.; Castle, J.; Bartel, D.P.; 
Linsley, P.S.; Johnson, J.M. Microarray analysis shows that some microRNAs downregulate 
large numbers of target mRNAs. Nature 2005, 433, 769–773. 
27.  Grimson, A.; Farh, K.K.; Johnston, W.K.; Garrett-Engele, P.; Lim, L.P.; Bartel, D.P. MicroRNA 
targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 2007, 27, 91–105. 
28.  Maziere, P.; Enright, A.J. Prediction of microRNA targets. Drug Discov. Today  2007,  12,  
452–458. 
29.  Bartonicek, N.; Enright, A.J. SylArray: A web server for automated detection of miRNA effects 
from expression data. Bioinformatics 2010, 26, 2900–2911. 
30.  Heikham, R.; Shankar, R. Flanking region sequence information to refine microRNA target 
predictions. J. Biosci. 2010, 35, 105–118. Int. J. Mol. Sci. 2012, 13 858 
 
 
31.  Maragkakis, M.; Reczko, M.; Simossis, V.A.; Alexiou, P.; Papadopoulos, G.L.; Dalamagas, T.; 
Giannopoulos, G.; Goumas, G.; Koukis, E.; Kourtis, K.; et al. DIANA-microT web server: 
Elucidating microRNA functions through target prediction. Nucleic Acids Res.  2009,  37,  
W273–W276. 
32.  Kertesz, M.; Iovino, N.; Unnerstall, U.; Gaul, U.; Segal, E. The role of site accessibility in 
microRNA target recognition. Nat. Genet. 2007, 39, 1278–1284. 
33.  Thadani, R.; Tammi, M.T. MicroTar: Predicting microRNA targets from RNA duplexes. BMC 
Bioinformatics 2006, 7, S20. 
34.  Kim, S.K.; Nam, J.W.; Rhee, J.K.; Lee, W.J.; Zhang, B.T. miTarget: microRNA target gene 
prediction using a support vector machine. BMC Bioinformatics 2006, 7, 411. 
35.  Miranda, K.C.; Huynh, T.; Tay, Y.; Ang, Y.S.; Tam, W.L.; Thomson, A.M.; Lim, B.; Rigoutsos, I. 
A pattern-based method for the identification of MicroRNA binding sites and their 
corresponding heteroduplexes. Cell 2006, 126, 1203–1217. 
36.  Kruger, J.; Rehmsmeier, M. RNAhybrid: microRNA target prediction easy, fast and flexible. 
Nucleic Acids Res. 2006, 34, W451–W454. 
37.  Krek, A.; Grün, D.; Poy, M.N.; Wolf, R.; Rosenberg, L.; Epstein, E.J.; MacMenamin, P.;  
da Piedade, I.; Gunsalus, K.C.; Stoffel, M.; et al. Combinatorial microRNA target predictions. 
Nat. Genet. 2005, 37, 495–500. 
38.  John, B.; Enright, A.J.; Aravin, A.; Tuschl, T.; Sander, C.; Marks, D.S. Human MicroRNA 
targets. PLoS Biol. 2004, 2, e363. 
39.  Lewis, B.P.; Shih, I.H.; Jones-Rhoades, M.W.; Bartel, D.P.; Burge, C.B. Prediction of 
mammalian microRNA targets. Cell 2003, 115, 787–798. 
40.  Lewis, B.P.; Burge, C.B.; Bartel, D.P. Conserved seed pairing, often flanked by adenosines, 
indicates that thousands of human genes are microRNA targets. Cell 2005, 120, 15–20. 
41.  Li, L.; Xu, J.; Yang, D.; Tan, X.; Wang, H. Computational approaches for microRNA studies: A 
review. Mamm. Genome 2010, 21, 1–12. 
42.  Huarte, M.; Rinn, J.L. Large non-coding RNAs: Missing links in cancer? Hum. Mol. Genet. 2010, 
19, 152–161. 
43.  MiRBase. Available online: http://microrna.sanger.ac.uk/sequences/index.shtml (accessed on 16 
January 2012).   
44.  MiRBase. Available online: http://www.miRBase.org/ (accessed on 16 January 2012).   
45.  Zhang, L.; Huang, J.; Yang, N.; Greshock, J.; Megraw, M.S.; Giannakakis, A.; Liang, S.;  
Naylor, T.L.; Barchetti, A.; Ward, M.R.; et al. MicroRNAs exhibit high frequency genomic 
alterations in human cancer. Proc. Natl. Acad. Sci. USA 2006, 103, 9136–9141. 
46.  Calin, G.A.; Dumitru, C.D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; 
Keating, M.; Rai, K.; et al. Frequent deletions and down-regulation of micro- RNA genes miR15 
and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 2002, 99, 
15524–1559. 
47.  Cimmino, A.; Calin, G.A.; Fabbri, M.; Iorio, M.V.; Ferracin, M.; Shimizu, M.; Wojcik, S.E.; 
Aqeilan, R.I.; Zupo, S.; Dono, M.; et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. 
Proc. Natl. Acad. Sci. USA 2005, 102, 13944–13949. Int. J. Mol. Sci. 2012, 13 859 
 
 
48.  Lewis, B.P.; Burge, C.B.; Bartel, D.P. Conserved seed pairing, often flanked by adenosines, 
indicates that thousands of human genes are microRNA targets. Cell 2005, 120, 15–20. 
49.  Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; 
Ebert, B.L.; Mak, R.H.; Ferrando, A.A.; et al. MicroRNA expression profiles classify human 
cancers. Nature 2005, 435, 834–838. 
50.  Volinia, S.; Calin, G.A.; Liu, C.G.; Ambs, S.; Cimmino, A.; Petrocca, F.; Visone, R.; Iorio, M.; 
Roldo, C.; Ferracin, M.; et al. A microRNA expression signature of human solid tumors defines 
cancer gene targets. Proc. Natl. Acad. Sci. USA 2006, 103, 2257–2261. 
51.  Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6, 
857–866. 
52.  Cho, W.C. MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets for 
therapy. Int. J. Biochem. Cell Biol. 2010, 42, 1273–1281. 
53.  Cho, W.C. MicroRNAs in cancer—from research to therapy. Biochim. Biophys. Acta 2010, 1805, 
209–217. 
54.  Luo, X.; Burwinkel, B.; Tao, S.; Brenner, H. MicroRNA signatures: Novel biomarker for 
colorectal cancer? Cancer Epidemiol. Biomarkers Prev. 2011, 20, 1272–1286. 
55.  Katayama, S.; Tomaru, Y.; Kasukawa, T.; Waki, K.; Nakanishi, M.; Nakamura, M.; Nishida, H.; 
Yap, C.C.; Suzuki, M.; Kawai, J.; et al. Antisense transcription in the mammalian transcriptome. 
Science 2005, 309, 1564–1566. 
56.  Khalil, A.M.; Guttman, M.; Huarte, M.; Garber, M.; Raj, A.; Rivea Morales, D.; Thomas, K.; 
Presser, A.; Bernstein, B.E.; van Oudenaarden, A.; et al. Many human large intergenic 
noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. 
Proc. Natl. Acad. Sci. USA 2009, 106, 11667–11672. 
57.  Huarte, M.; Guttman, M.; Feldser, D.; Garber, M.; Koziol, M.J.; Kenzelmann-Broz, D.; Khalil, 
A.M.; Zuk, O.; Amit, I.; Rabani, M.; et al. A large intergenic noncoding RNA induced by p53 
mediates global gene repression in the p53 response. Cell 2010, 142, 409–419. 
58.  Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; 
Ebert, B.L.; Mak, R.H.; Ferrando, A.A.; et al. MicroRNA expression profiles classify human 
cancers. Nature 2005, 435, 834–838. 
59.  Michael, M.Z.; O’Connor, S.M.; van Holst Pellekaan, N.G.; Young, G.P.; James, R.J. Reduced 
accumulation of specific microRNAs in colorectal neoplasia. Mol. Cancer Res. 2003, 1, 882–891. 
60.  Cummins, J.M.; He, Y.; Leary, R.J.; Pagliarini, R.; Diaz, L.A., Jr.; Sjoblom, T.; Barad, O.; 
Bentwich, Z.; Szafranska, A.E.; Labourier, E.; et al. The colorectal microRNAome. Proc. Natl. 
Acad. Sci. USA 2006, 103, 3687–3692. 
61.  Bandrés, E.; Cubedo, E.; Agirre, X.; Malumbres, R.; Zárate, R.; Ramirez, N.; Abajo, A.; Navarro, 
A.; Moreno, I.; Monzó, M.; et al. Identification by Real-time PCR of 13 mature microRNAs 
differentially expressed in colorectal cancer and non-tumoral tissues. Mol. Cancer 2006, 5, 29. 
62.  Pawa, N.; Arulampalam, T.; Norton, J.D. Screening for colorectal cancer: Established and 
emerging modalities. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 711–722. 
63.  Fearon, E.R.; Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell  1990,  61,  
759–767. Int. J. Mol. Sci. 2012, 13 860 
 
 
64.  Nagel, R.; le Sage, C.; Diosdado, B.; van der Waal, M.; Oude Vrielink, J.A.; Bolijn, A.;  
Meijer, G.A.; Agami, R. Regulation of the adenomatous polyposis coli gene by the miR-135 
family in colorectal cancer. Cancer Res. 2008, 68, 5795–5802. 
65.  Kumar, M.S.; Lu, J.; Mercer, K.L.; Golub, T.R.; Jacks, T. Impaired microRNA processing 
enhances cellular transformation and tumorigenesis. Nat. Genet. 2007, 39, 673–677. 
66.  Tsang, W.P.; Kwok, T.T. The miR-18a* microRNA functions as a potential tumor suppressor by 
targeting on K-Ras. Carcinogenesis 2009, 30, 953–959. 
67.  Guo, C.; Sah, J.F.; Beard, L.; Willson, J.K.; Markowitz, S.D.; Guda, K. The noncoding RNA, 
miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase 
signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer  2008,  47,  
939–946. 
68.  Natalwala, A.; Spychal, R.; Tselepis, C. Epithelial-mesenchymal transition mediated 
tumourigenesis in the gastrointestinal tract. World J. Gastroenterol. 2008, 14, 3792–3797. 
69.  Strillacci, A.; Griffoni, C.; Sansone, P.; Paterini, P.; Piazzi, G.; Lazzarini, G.; Spisni, E.; Pantaleo, 
M.A.; Biasco, G.; Tomasi, V. MiR-101 downregulation is involved in cyclooxygenase-2 
overexpression in human colon cancer cells. Exp. Cell Res. 2009, 315, 1439–1447. 
70.  Hudson, J.D.; Shoaibi, M.A.; Maestro, R.; Carnero, A.; Hannon, G.J.; Beach, D.H. A 
proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med.  1999,  190,  
1375–1382. 
71.  Ohkawara, T.; Takeda, H.; Nishihira, J.; Miyashita, K.; Nihiwaki, M.; Ishiguro, Y.; Takeda, K.; 
Akira, S.; Iwanaga, T.; Sugiyama, T.; et al. Macrophage migration inhibitory factor contributes 
to the development of acute dextran sulphate sodium-induced colitis in Toll-like receptor 4 
knockout mice. Clin. Exp. Immunol. 2005, 141, 412–421. 
72.  Wilson, J.M.; Coletta, P.L.; Cuthbert, R.J.; Scott, N.; MacLennan, K.; Hawcroft, G.; Leng, L.; 
Lubetsky, J.B.; Jin, K.K.; Lolis, E.; et al. Macrophage migration inhibitory factor promotes 
intestinal tumorigenesis. Gastroenterology 2005, 129, 1485–1503. 
73.  He, X.X.; Chen, K.; Yang, J.; Li, X.Y.; Gan, H.Y.; Liu, C.Y.; Coleman, T.R.; Al-Abed, Y. 
Macrophage migration inhibitory factor promotes colorectal cancer. Mol. Med. 2009, 15, 1–10. 
74.  Shah, M.A.; Schwartz, G.K. Cell cycle-mediated drug resistance: an emerging concept in cancer 
therapy. Clin. Cancer Res. 2001, 7, 2168–2181. 
75.  Mirjolet, J.F.; Barberi-Heyob, M.; Merlin, J.L.; Marchal, S.; Etienne, M.C.; Milano, G.; Bey, P. 
Thymidylate synthase expression and activity: Relation to S-phase parameters and 5-fluorouracil 
sensitivity. Br. J. Cancer 1998, 78, 62–68. 
76.  McGinn, C.J.; Pestalozzi, B.C.; Drake, J.C.; Glennon, M.C.; Kunugi, K.; Otterson, G.;  
Allegra, C.J.; Johnston, P.G.; Kinsella, T.J. Cell cycle regulation of the G0/G1 transition in  
5-fluorouracil-sensitive and -resistant human colon cancer cell lines. Cancer J. 2000, 6, 234–242. 
77.  Geller, J.I.; Szekely-Szucs, K.; Petak, I.; Doyle, B.; Houghton, J.A. P21Cip1 is a critical 
mediator of the cytotoxic action of thymidylate synthase inhibitors in colorectal carcinoma cells. 
Cancer Res. 2004, 64, 6296–6303. 
78.  Georges, S.A.; Biery, M.C.; Kim, S.Y.; Schelter, J.M.; Guo, J.; Chang, A.N.; Jackson, A.L.; 
Carleton, M.O.; Linsley, P.S.; Cleary, M.A.; et al. Coordinated regulation of cell cycle transcripts 
by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res. 2008, 68, 10105–10112. Int. J. Mol. Sci. 2012, 13 861 
 
 
79.  Braun, C.J.; Zhang, X.; Savelyeva, I.; Wolff, S.; Moll, U.M.; Schepeler, T.; Ørntoft, T.F.; 
Andersen, C.L.; Dobbelstein, M. p53-Responsive micrornas 192 and 215 are capable of inducing 
cell cycle arrest. Cancer Res. 2008, 68, 10094–10104. 
80.  Schetter, A.J.; Leung, S.Y.; Sohn, J.J.; Zanetti, K.A.; Bowman, E.D.; Yanaihara, N.; Yuen, S.T.; 
Chan, T.L.; Kwong, D.L.; Au, G.K.; et al. MicroRNA expression profiles associated with 
prognosis and therapeutic outcome in colon adenocarcinoma. J. Am. Med. Assoc. 2008, 299, 
425–436. 
81.  Chen, X.; Guo, X.; Zhang, H.; Xiang, Y.; Chen, J.; Yin, Y.; Cai, X.; Wang, K.; Wang, G.;  
Ba, Y.; et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009, 28,  
1385–1392. 
82.  Kogo, R.; Shimamura, T.; Mimori, K.; Kawahara, K.; Imoto, S.; Sudo, T.; Tanaka, F.;  
Shibata, K.; Suzuki, A.; Komune, S.; et al. Long noncoding RNA HOTAIR regulates  
Polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal 
cancers. Cancer Res. 2011, 71, 6320–6326. 
83.  Blower, P.E.; Verducci, J.S.; Lin, S.; Zhou, J.; Chung, J.H.; Dai, Z.; Liu, C.G.; Reinhold, W.; 
Lorenzi, P.L.; Kaldjian, E.P.; et al. MicroRNA expression profiles for the NCI-60 cancer cell 
panel. Mol. Cancer Ther. 2007, 6, 1483–1491. 
84.  Blower, P.E.; Chung, J.H.; Verducci, J.S.; Lin, S.; Park, J.K.; Dai, Z.; Liu, C.G.;   
Schmittgen, T.D.; Reinhold, W.C.; Croce, C.M.; et al. MicroRNAs modulate the 
chemosensitivity of tumor cells. Mol. Cancer Ther. 2008, 7, 1–9. 
85.  Longley, D.B.; Allen, W.L.; Johnston, P.G. Drug resistance, predictive markers and 
pharmacogenomics in colorectal cancer. Biochim. Biophys. Acta 2006, 1766, 184–196. 
86.  Szakacs, G.; Paterson, J.K.; Ludwig, J.A.; Booth-Genthe, C.; Gottesman, M.M. Targeting 
multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5, 219–234. 
87.  Iwasa, Y.; Nowak, M.A.; Michor, F. Evolution of resistance during clonal expansion. Genetics 
2006, 172, 2557–2566. 
88.  Roberti, A.; La Sala, D.; Cinti, C. Multiple genetic and epigenetic interacting mechanisms 
contribute to clonally selection of drug-resistant tumors: Current views and new therapeutic 
prospective. J. Cell. Physiol. 2006, 207, 571–581. 
89.  Glasspool, R.M.; Teodoridis, J.M.; Brown, R. Epigenetics as a mechanism driving polygenic 
clinical drug resistance. Br. J. Cancer 2006, 94, 1087–1092. 
90.  Fojo, T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and 
amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug 
Resist. Updat. 2007, 10, 59–67. 
91.  Duesberg, P.; Li, R.; Sachs, R.; Fabarius, A.; Upender, M.B.; Hehlmann, R. Cancer drug 
resistance: the central role of the karyotype. Drug Resist. Updat. 2007, 10, 51–58. 
92.  Ragusa, M.; Majorana, A.; Statello, L.; Maugeri, M.; Salito, L.; Barbagallo, D.; Guglielmino, M.R.; 
Duro, L.R.; Angelica, R.; Caltabiano, R.; Biondi, A.; et al. Specific alterations of microRNA 
transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. 
Mol. Cancer Ther. 2010, 9, 3396–3409. Int. J. Mol. Sci. 2012, 13 862 
 
 
93.  Nakajima, G.; Hayashi, K.; Xi, Y.; Kudo, K.; Uchida, K.; Takasaki, K.; Yamamoto, M.; Ju, J. 
Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 
in colon cancer. Cancer Genomics Proteomics 2006, 3, 317–3124. 
94.  Fujita, Y.; Kojima, K.; Hamada, N.; Ohhashi, R.; Akao, Y.; Nozawa, Y.; Deguchi, T.; Ito, M. 
Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem. 
Biophys. Res. Commun. 2008, 377, 114–119. 
95.  Valeri, N.; Gasparini, P.; Braconi, C.; Paone, A.; Lovat, F.; Fabbri, M.; Sumani, K.M.; Alder, H.; 
Amadori, D.; Patel, T.; et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating 
human DNA MutS homolog 2 (hMSH2). Proc. Natl. Acad. Sci. USA 2010, 107, 21098–21103. 
96.  Zhou, J.; Zhou, Y.; Yin, B.; Hao, W.; Zhao, L.; Ju, W.; Bai, C. 5-Fluorouracil and oxaliplatin 
modify the expression profiles of microRNAs in human colon cancer cells in vitro. Oncol. Rep. 
2010, 23, 121–128. 
97.  Svoboda, M.; Izakovicova Holla, L.; Sefr, R.; Vrtkova, I.; Kocakova, I.; Tichy, B.; Dvorak, J. 
Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine 
chemoradiotherapy of rectal cancer. Int. J. Oncol. 2008, 33, 541–547. 
98.  Saunders, M.A.; Liang, H.; Li, W.H. Human polymorphism at microRNAs and microRNA target 
sites. Proc. Natl. Acad. Sci. USA 2007, 104, 3300–3305. 
99.  Xing, J.; Wan, S.; Zhou, F.; Qu, F.; Li, B.; Myers, R.E.; Fu, X.; Palazzo, J.P.; He, X.;  
Chen, Z.; et al. Genetic polymorphisms in pre-microRNA genes as prognostic markers of 
colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 2011, in press. 
100.  Boni, V.; Zarate, R.; Villa, J.C.; Bandrés, E.; Gomez, M.A.; Maiello, E.; Garcia-Foncillas, J.; 
Aranda, E. Role of primary miRNA polymorphic variants in metastatic colon cancer patients 
treated with 5-fluorouracil and irinotecan. Pharmacogenomics J. 2010, 29, 1–8. 
101.  Landi, D.; Gemignani, F.; Naccarati, A.; Pardini, B.; Vodicka, P.; Vodickova, L.; Novotny, J.; 
Forsti, A.; Hemminki, K.; Canzian, F. Polymorphisms within micro-RNA-binding sites and risk 
of sporadic colorectal cancer. Carcinogenesis 2008, 29, 579–584. 
102.  Smits, K.M.; Paranjape, T.; Nallur, S.; Wouters, K.A.; Weijenberg, M.P.; Schouten, L.J.;  
van den Brandt, P.A.; Bosman, F.; Weidhaas, J.B.; van Engeland, M. A let-7 microRNA SNP in 
the KRAS 3'-UTR is prognostic in early-stage colorectal cancer. Clin. Cancer Res.  2011,  
in press. 
103.  Schepeler, T.; Reinert, J.T.; Ostenfeld, M.S.; Christensen, L.L.; Silahtaroglu, A.N.; Dyrskjøt, L.; 
Wiuf, C.; Sørensen, F.J.; Kruhøffer, M.; Laurberg, S.; et al. Diagnostic and prognostic 
microRNAs in stage II colon cancer. Cancer Res. 2008, 68, 6416–6424. 
104.  Wang, C.J.; Zhou, Z.G.; Wang, L.; Yang, L.; Zhou, B.; Gu, J.; Chen, H.Y.; Sun, X.F. 
Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. 
Dis. Markers 2009, 26, 27–34. 
105.  Slaby, O.; Svoboda, M.; Fabian, P.; Smerdova, T.; Knoflickova, D.; Bednarikova, M.;  
Nenutil, R.; Vyzula, R. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related 
to clinicopathologic features of colorectal cancer. Oncology 2007, 72, 397–402. 
106.  Motoyama, K.; Inoue, H.; Takatsuno, Y.; Tanaka, F.; Mimori, K.; Uetake, H.; Sugihara, K.; Mori, 
M. Over- and under-expressed microRNAs in human colorectal cancer. Int. J. Oncol. 2009, 34, 
1069–1075. Int. J. Mol. Sci. 2012, 13 863 
 
 
107.  Lanza, G.; Ferracin, M.; Gafà, R.; Veronese, A.; Spizzo, R.; Pichiorri, F.; Liu, C.G.; Calin, G.A.; 
Croce, C.M.; Negrini, M. mRNA/microRNA gene expression profile in microsatellite unstable 
colorectal cancer. Mol. Cancer 2007, 6, doi:10.1186/1476-4598-6-54. 
108.  Wang, J.; Chen, J.; Chang, P.; LeBlanc, A.; Li, D.; Abbruzzesse, J.L.; Frazier, M.L.;  
Killary, A.M.; Sen, S. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as 
novel blood-based biomarkers of disease. Cancer Prev. Res. (Phila Pa) 2009, 2, 807–813. 
109.  Van Deerlin, V.M.; Gill, L.H.; Nelson, P.T. Optimizing gene expression analysis in archival 
brain tissue. Neurochem. Res. 2002, 27, 993–1003. 
110.  Nelson, P.T.; Baldwin, D.A.; Scearce, L.M.; Oberholtzer, J.C.; Tobias, J.W.; Mourelatos, Z. 
Microarray-based, high-throughput gene expression profiling of microRNAs. Nat. Methods 2004, 
1,155–161. 
111.  Li, J.; Smyth, P.; Flavin, R.; Cahill, S.; Denning, K.; Aherne, S.; Guenther, S.M.; O’Leary, J.J.; 
Sheils, O. Comparison of miRNA expression patterns using total RNA extracted from matched 
samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC 
Biotechnol. 2007, 7, doi:10.1186/1472-6750-7-36. 
112.  Ng, E.K.; Chong, W.W.; Jin, H.; Lam, E.K.; Shin, V.Y.; Yu, J.; Poon, T.C.; Ng, S.S.; Sung, J.J. 
Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential 
marker for colorectal cancer screening. Gut 2009, 58, 1375–1381. 
113. Link, A.; Balaguer, F.; Shen, Y.; Nagasaka, T.; Lozano, J.J.; Boland, C.R.; Goel, A. Fecal 
MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol. Biomarkers 
Prev. 2010, 19, 1766–1774. 
114. Tsujiura, M.; Ichikawa, D.; Komatsu, S.; Shiozaki, A.; Takeshita, H.; Kosuga, T.; Konishi, H.; 
Morimura, R.; Deguchi, K.; Fujiwara, H. Circulating microRNAs in plasma of patients with 
gastric cancers. Br. J. Cancer 2010, 102, 1174–1179. 
115. Heneghan, H.M.; Miller, N.; Lowery, A.J.; Sweeney, K.J.; Newell, J.; Kerin, M.J. Circulating 
microRNAs as novel minimally invasive biomarkers for breast cancer. Ann. Surg. 2010, 251, 
499–505. 
116. Hu, Z.; Chen, X.; Zhao, Y.; Tian, T.; Jin, G.; Shu, Y.; Chen, Y.; Xu, L.; Zen, K.; Zhang, C. 
Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling 
predict survival of non-small-cell lung cancer. J. Clin. Oncol. 2010, 28, 1721–1726. 
117.  Lawrie, C.H.; Gal, S.; Dunlop, H.M.; Pushkaran, B.; Liggins, A.P.; Pulford, K.; Banham, A.H.; 
Pezzella, F.; Boultwood, J.; Wainscoat, J.S. Detection of elevated levels of tumour-associated 
microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008, 141, 
672–675. 
118. Qu, H.; Xu, W.; Huang, Y.; Yang, S. Circulating miRNAs: Promising biomarkers of human 
cancer. Asian Pac. J. Cancer Prev. 2011, 12, 1117–1125. 
119.  Elmén, J.; Lindow, M.; Schütz, S.; Lawrence, M.; Petri, A.; Obad, S.; Lindholm, M.; Hedtjärn, M.; 
Hansen, H.F.; Berger, U.; et al. LNA-mediated microRNA silencing in non-human primates. 
Nature 2008, 452, 896–899. 
120. Krützfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K.G.; Tuschl, T.; Manoharan, M.; Stoffel, M. 
Silencing of microRNAs in vivo with “antagomirs”. Nature 2005, 438, 685–689. Int. J. Mol. Sci. 2012, 13 864 
 
 
121. Esau, C.; Davis, S.; Murray, S.F.; Yu, X.X.; Pandey, S.K.; Pear, M.; Watts, L.; Booten, S.L.; 
Graham, M.; McKay, R.; et al. miR-122 regulation of lipid metabolism revealed by in vivo 
antisense targeting. Cell Metab. 2006, 3, 87–98. 
122. Krichevsky, A.M.; Gabriely, G. miR-21: A small multi-faceted RNA. J. Cell. Mol. Med. 2009, 
13, 39–53. 
123.  Si, M.L.; Zhu, S.; Wu, H.; Lu, Z.; Wu, F.; Mo, Y.Y. miR-21-mediated tumor growth. Oncogene 
2007, 26, 2799–2803. 
124.  Gumireddy, K.; Young, D.D.; Xiong, X.; Hogenesch, J.B.; Huang, Q.; Deiters, A.   
Small-molecule inhibitors of microrna miR-21 function. Angew. Chem. Int. Ed. Engl. 2008, 47, 
7482–7484. 
125. Ebert, M.S.; Neilson, J.R.; Sharp, P.A. MicroRNA sponges: Competitive inhibitors of small 
RNAs in mammalian cells. Nat. Methods 2007, 4, 721–726. 
126. Xiao, J.; Yang, B.; Lin, H.; Lu, Y.; Luo, X.; Wang, Z. Novel approaches for gene-specific 
interference via manipulating actions of microRNAs: Examination on the pacemaker channel 
genes HCN2 and HCN4. J. Cell. Physiol. 2007, 212, 285–292. 
127. Ji, Q.; Hao, X.; Meng, Y.; Zhang, M.; Desano, J.; Fan, D.; Xu, L. Restoration of tumor 
suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008, 
8, doi:10.1186/1471-2407-8-266. 
128.  Ji, Q.; Hao, X.; Zhang, M.; Tang, W.; Yang, M.; Li, L.; Xiang, D.; Desano, J.T.; Bommer, G.T.; 
Fan, D.; et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS 
One 2009, 4, e6816. 
129.  Pirollo, K.F.; Xu, L.; Chang, E.H. Non-viral gene delivery for p53. Curr. Opin. Mol. Ther. 2000, 
2, 168–175. 
130. Xu, L.; Pirollo, K.F.; Chang, E.H. Tumor-targeted p53-gene therapy enhances the efficacy of 
conventional chemo/radiotherapy. J. Control. Release 2001, 74, 115–128. 
131.  Ibrahim, A.F.; Weirauch, U.; Thomas, M.; Grunweller, A.; Hartmann, R.K.; Aigner, A. MiRNA 
replacement therapy through PEI-mediated in vivo delivery of miR-145 or miR-33a in colon 
carcinoma. Cancer Res. 2011, 71, 5214–5224. 
132. Trang, P.; Wiggins, J.F.; Daige, C.L.; Cho, C.; Omotola, M.; Brown, D.; Weidhaas, J.B.;  
Bader, A.G.; Slack, F.J. Systemic delivery of tumor suppressor microRNA mimics using a 
neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 2011, 19, 1116–1122. 
133. Landen, C.N., Jr.; Chavez-Reyes, A.; Bucana, C.; Schmandt, R.; Deavers, M.T.; Lopez-Berestein, G.; 
Sood, A.K. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering 
RNA delivery. Cancer Res. 2005, 65, 6910–6918. 
134. Takeshita, F.; Patrawala, L.; Osaki, M.; Takahashi, R.U.; Yamamoto, Y.; Kosaka, N.; Kawamata, 
M.; Kelnar, K.; Bader, A.G.; Brown, D.; et al. Systemic delivery of synthetic microRNA-16 
inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. 
Mol. Ther. 2010, 18, 181–187. 
135. Bonci, D.; Coppola, V.; Musumeci, M.; Addario, A.; Giuffrida, R.; Memeo, L.; D’Urso, L.; 
Pagliuca, A.; Biffoni, M.; Labbaye, C.; et al. The miR-15a-miR-16-1 cluster controls prostate 
cancer by targeting multiple oncogenic activities. Nat. Med. 2008, 14, 1271–1277. Int. J. Mol. Sci. 2012, 13 865 
 
 
136. Liu, C.; Kelnar, K.; Liu, B.; Chen, X.; Calhoun-Davis, T.; Li, H.; Patrawala, L.; Yan, H.;  
Jeter, C.; Honorio, S.; et al. The microRNA miR-34a inhibits prostate cancer stem cells and 
metastasis by directly repressing CD44. Nat. Med. 2011, 17, 211–215. 
137. Cho, W.C. Molecular diagnostics for monitoring and predicting therapeutic effect in cancer. 
Expert Rev. Mol. Diagn. 2011, 11, 9–12. 
138.  Zhang, W.; Dahlberg, J.E.; Tam, W. MiRNAs in tumorigenesis: A primer. Am. J. Pathol. 2007, 
171, 728–738. 
139.  Henry, J.C.; Azevedo-Pouly, A.C.; Schmittgen, T.D. microRNA replacement therapy for cancer. 
Pharm. Res. 2011, 28, 3030–3042. 
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 